BioNTech SE (NASDAQ:BNTX) went up by 4.05% from its latest closing price compared to the recent 1-year high of $464.00. The company’s stock price has collected -5.28% of loss in the last five trading sessions. The Wall Street Journal reported 4 hours ago that CDC Panel Recommends Pfizer Covid-19 Boosters for Seniors, Certain Adults With Underlying Medical Conditions
Is It Worth Investing in BioNTech SE (NASDAQ :BNTX) Right Now?
BioNTech SE (NASDAQ:BNTX) scored a price-to-earnings ratio above its average ratio, recording 18.36 x from its present earnings ratio. Opinions of the stock are interesting as 4 analysts out of 13 who provided ratings for BioNTech SE declared the stock was a “buy,” while 0 rated the stock as “overweight,” 7 rated it as “hold,” and 2 as “sell.”
The average price from analysts is $296.03, which is -$20.12 below the current price. BNTX currently public float of 215.94M and currently shorts hold a 0.98% ratio of that float. Today, the average trading volume of BNTX was 4.13M shares.
BNTX’s Market Performance
BNTX stocks went down by -5.28% for the week, with a monthly drop of -4.13% and a quarterly performance of 54.96%, while its annual performance rate touched 453.02%. The volatility ratio for the week stands at 5.04% while the volatility levels for the past 30 days are set at 5.39% for BioNTech SE. The simple moving average for the period of the last 20 days is 1.93% for BNTX stocks with a simple moving average of 81.98% for the last 200 days.
Analysts’ Opinion of BNTX
Many brokerage firms have already submitted their reports for BNTX stocks, with Bryan Garnier repeating the rating for BNTX by listing it as a “Buy.” The predicted price for BNTX in the upcoming period, according to Bryan Garnier is $451 based on the research report published on August 11th of the current year 2021.
Wolfe Research, on the other hand, stated in their research note that they expect to see BNTX reach a price target of $248. The rating they have provided for BNTX stocks is “Outperform” according to the report published on July 19th, 2021.
Redburn gave a rating of “Sell” to BNTX, setting the target price at $146 in the report published on June 16th of the current year.
BNTX Trading at 5.03% from the 50-Day Moving Average
After a stumble in the market that brought BNTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -23.92% of loss for the given period.
Volatility was left at 5.39%, however, over the last 30 days, the volatility rate increased by 5.04%, as shares sank -6.13% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +66.50% upper at present.
During the last 5 trading sessions, BNTX fell by -5.28%, which changed the moving average for the period of 200-days by +180.82% in comparison to the 20-day moving average, which settled at $345.16. In addition, BioNTech SE saw 333.01% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for BNTX
Current profitability levels for the company are sitting at:
- -55.27 for the present operating margin
- +87.76 for the gross margin
The net margin for BioNTech SE stands at +3.15. The total capital return value is set at -23.29, while invested capital returns managed to touch 1.34. Equity return is now at value 158.10, with 95.10 for asset returns.
Based on BioNTech SE (BNTX), the company’s capital structure generated 17.51 points at debt to equity in total, while total debt to capital is 14.90. Total debt to assets is 10.36, with long-term debt to equity ratio resting at 16.84. Finally, the long-term debt to capital ratio is 14.33.
When we switch over and look at the enterprise to sales, we see a ratio of 1.08, with the company’s debt to enterprise value settled at 0.02. The receivables turnover for the company is 4.86 and the total asset turnover is 0.29. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.70.